| Literature DB >> 21569466 |
Mogens Fenger1, Allan Linneberg, Torben Jørgensen, Sten Madsbad, Karen Søbye, Jesper Eugen-Olsen, Jørgen Jeppesen.
Abstract
BACKGROUND: Several attempts to decipher the genetics of hypertension of unknown causes have been made including large-scale genome-wide association analysis (GWA), but only a few genes have been identified. Unsolved heterogeneity of the regulation of blood pressure and the shortcomings of the prevailing monogenic approach to capture genetic effects in a polygenic condition are the main reasons for the modest results. The level of the blood pressure is the consequence of the genotypic state of the presumably vast network of genes involved in regulating the vascular tonus and hence the blood pressure. Recently it has been suggested that components of the sphingolipid metabolism pathways may be of importance in vascular physiology. The basic metabolic network of sphingolipids has been established, but the influence of genetic variations on the blood pressure is not known. In the approach presented here the impact of genetic variations in the sphingolipid metabolism is elucidated by a two-step procedure. First, the physiological heterogeneity of the blood pressure is resolved by a latent class/structural equation modelling to obtain homogenous subpopulations. Second, the genetic effects of the sphingolipid metabolism with focus on de novo synthesis of ceramide are analysed. The model does not assume a particular genetic model, but assumes that genes operate in networks.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21569466 PMCID: PMC3115901 DOI: 10.1186/1471-2156-12-44
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Summary of the indicators and covariates in the Monica study included in the LCA-SEM analysis.
| Mean (SD) | |||
|---|---|---|---|
| All | Women | Men | |
| Number | 2,523 | 1,257 | 1,266 |
| Age | 43.6 (10.8) | 43.2 (10.8) | 44.0 (10.7) |
| Sitting systolic | 129 (19) | 127 (19) | 132 (19)** |
| Sitting diastolic | 82 (11) | 81 (10) | 84 (11)** |
| Supine systolic | 129 (18) | 127 (19) | 131 (17)** |
| Supine diastolic | 80 (10) | 78 (10) | 82 (10)** |
| Day systolic | 131 (14) | 127 (14) | 134 (13)** |
| Day diastolic | 78 (10) | 75 (10) | 81 (9)** |
| Night systolic | 112 (14) | 110 (15) | 115 (14)** |
| Night diastolic | 64 (9) | 62 (9) | 66 (9)** |
| 24 hour systolic | 126 (14) | 123 (14) | 129 (13)** |
| 24 hour diastolic | 74 (9) | 71 (9) | 77 (9)** |
| Ultrasound left site systolic | 131 (21) | 130 (22) | 132 (19)** |
| Ultrasound left site diastolic | 79 (11) | 78 (12) | 81 (11)** |
| Ultrasound right site systolic | 127 (21) | 126 (22) | 128 (19)* |
| Ultrasound right site diastolic | 78 (11) | 77 (11) | 80 (11)** |
| Ultrasound mean systolic | 129 (20) | 128 (21) | 130 (18)* |
| Ultrasound mean diastolic | 79 (11) | 77 (11) | 80 (10)** |
| Total cholesterol (mmol/L) | 6.2 (1.1) | 6.1 (1.1) | 6.2 (1.1) |
| LDL cholesterol (mmol/L) | 4.0 (1.0) | 3.9 (1.0) | 4.1 (1.0)** |
| VLDL cholesterol (mmol/L) | 0.65 (0.37) | 0.58 (0.29) | 0.72 (0.42)** |
| T riglycerides (mmol/L) | 1.46 (1.04) | 1.29 (0.88) | 1.63 (1.16)** |
| HDL cholesterol (mmol/L) | 1.44 (0.41) | 1.60 (0.43) | 1.29 (0.34)** |
| WH ratio | 0.88 (0.09) | 0.82 (0.06) | 0.94 (0.06)** |
| BMI (kg/height2) | 26.0 (4.2) | 25.4 (4.5) | 26.5 (3.8)** |
| Insulin (pmol/L) | 38 (33) | 33.5 (26.4) | 42 (38)** |
| Glucose (mol/L) | 4.9 (1.1) | 4.7 (0.9) | 5.1 (1.2)** |
| HOMAres | 1.46 (1.73) | 1.24 (1.22) | 1.69 (2.10)** |
| ApoA1 (mmol/L) | 52.6 (21.4) | 56.0 (22.6) | 49.6 (20.0)** |
| ApoB (mmol/L) | 0.73 (0.24) | 0.70 (0.24) | 0.77 (0.24)** |
| ApoE (mmol/L) | 2.25 (1.18) | 2.30 (1.23) | 2.20 (1.13)* |
| Compliance | 0.57 (0.15) | 0.59 (0.15) | 0.55 (0.15)** |
| Aasi | 11.1 (3.3) | 10.6 (3.3) | 11.6 (3.3)** |
| Left ventricular mass | 80.5 (21.1) | 73.2 (17.5) | 88.0 (21.7)** |
| Supar (mg/L | 4.21(1.33) | 4.39 (1.31) | 4.01 (1.32)** |
| BNP (ng/L) | 76.0 (135.1) | 89.5 (115.7) | 61.7 (152.2)** |
| CRP (mg/L) | 3.2 (5.5) | 3.4 (6.1) | 3.1 (5.0) |
Day, Night and 24 hour blood pressures are mean of several measurements dyring the time period.
*p < 0.01; **p < 0.001 (difference between gender).
Figure 1The figure illustrates the simplified blood pressure model. The centre of the model is the latent "Vascular bed", which is in quotation mark as it represent a latent structure harboring all kinds of metabolic, physiologic and genetic processes in the arterial vessels. The physiological state of the vascular bed govern the diastolic and systolic blood pressures, which are the indicators in the model. The physiological state of the arterial vessels are influenced by several covariates as indicated in the figure. The covariates Apolipoproteins, Lipids, Antropometric, and Inflammatory covers several items each, but are not shown separately (see the text for details). Insulin and glucose is the variables used to calculate insulin resistance (HOMAres), but is not shown here as the measure is partly an intrinsic parameter in the vascular cells as well as many other tissues.
Figure 2Schematic outline of the ceramide/sphingosine-1-phosphate rheostat. Single arrows indicate irreversible processes, i.e. no enzymatic activities have been detected that reverses the metabolic pathway depicted by the arrows. Of particular interest is the degradation of sphingosine-1-phosphate to hexadcanal and phophoethanolamine which is a sink for sphingosine-1-phosphate irreversibly terminating its signalling activity.
Summary of the LCA-SEM partition using systolic and diastolic blood pressure as indicators
| Entropyb | |||||||
|---|---|---|---|---|---|---|---|
| Model | Number of subpopulations | Co-variates in decreasing order of significansa | With covariates | Change | % Normalizedd | Correlation of indicatorse | |
| Excluding CRP and BNP | |||||||
| 14 | CRP HomaRes Compliance Supar VLDL Aasi WH BNP ApoE | 0.789 | -2.3% | 66.9% | 81.8% | 71.4% | |
| 12 | CRP HomaRes Compliance Supar VLDL WH BNP ApoE Aasi ApoA1 | 0.788 | +5.3% | 61.1% | 75.0% | 83.3% | |
| 13 | CRP HomaRes Compliance Supar VLDL BNP ApoE | 0.747 | -9.3% | 64.1% | 79.5% | 84.6% | |
| 11 | CRP Compliance VLDL Homares Age BNP BMI ApoA1 | 0.724 | -1.0% | 50.0% | 69.1% | 81.8% | |
| 14 | HomaRes BNP Compliance Supar VLDL CRP Age BMI ApoA1 | 0.792 | +2.5% | 68.8% | 80.5% | 100.0% | |
| 12 | HomaRes CRP Supar BNP VLDL ApoA1 ApoE | 0.759 | -5.8% | 47.0% | 65.2% | 80.6% | |
| 14 | HomaRes BNP Compliance Supar VLDL CRP ApoA1 Age BMI | 0.801 | +5.8% | 68.7% | 80.8% | 28.6% | |
a CRP, C-reactive protein; HomaRes, insulin resistance;VLDL, very low densitity lipoprotein; Aasi, vessel stifness; WH, waist-hip ratio; BNP, B-type or brain natriuretic peptide; BMI, body mass index; Apo, apolipoprotein; Supar, soluble urokinase activator receptor.
b Entropy for the full model as defined in the MPlus programme (1 - standard entropy) for the error structure. Changes signifies deviation from the model without covariates.
c Ultrasound recording of systolic and diatolic blood pressure: UL4, left and rigth measurements are seperate indicators;
UL2, average of left and right systelic and diastolic blood pressure, respectively, are used as indicators
d Fraction of traits in all classes normalized by the LCA-SEM partition. Only the traits listed and the mode of blood pressure measurements are included in the calculation
e Fraction of indicators not correalted after LCA-SEM partition
Number of significant interactions in the subpopulations in the Supine model
| Partition: | model with covariates | Supine model without covariates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | 307 | 32,49% | 307 | 32,49% | 27 | 331 | 35,03% | 306 | 32,38% | |
| 2 | 111 | 318 | 33,65% | 316 | 33,44% | 113 | 325 | 34,39% | 325 | 34,39% | |
| 3 | 259 | 298 | 31,53% | 294 | 31,11% | 625 | 323 | 34,18% | 335 | 35,45% | |
| 4 | 33 | 230 | 24,34% | 334 | 35,34% | 104 | 338 | 35,77% | 338 | 35,77% | |
| 5 | 189 | 257 | 27,20% | 257 | 27,20% | 1 | 0 | 0,00% | 0 | 0,00% | |
| 6 | 301 | 321 | 33,97% | 310 | 32,80% | 30 | 320 | 33,86% | 320 | 33,86% | |
| 7 | 132 | 306 | 32,38% | 307 | 32,49% | 23 | 262 | 27,72% | 332 | 35,13% | |
| 8 | 89 | 238 | 25,19% | 238 | 25,19% | 89 | 304 | 32,17% | 305 | 32,28% | |
| 9 | 237 | 275 | 29,10% | 276 | 29,21% | 332 | 231 | 24,44% | 238 | 25,19% | |
| 10 | 141 | 334 | 35,34% | 337 | 35,66% | 279 | 295 | 31,22% | 295 | 31,22% | |
| 11 | 163 | 295 | 31,22% | 302 | 31,96% | 7 | 0 | 0,00% | 0 | 0,00% | |
| 12 | 40 | 336 | 35,56% | 336 | 35,56% | 544 | 226 | 23,92% | 232 | 24,55% | |
| 13 | 166 | 307 | 32,49% | 306 | 32,38% | 73 | 285 | 30,16% | 285 | 30,16% 32,28% | |
| 14 | 21 | 174 | 18,41% | 148 | 15,66% | 19 | 159 | 16,83% | 305 | ||
| Sum | 1.921 | 3.996 | 4.068 | 2.266 | 3.399 | 3.616 | |||||
| Average | 285,43 | 30,20% | 290,57 | 30,75% | 242,79 | 25,69% | 258,29 | 27,33% | |||
| Variance | 2.115 | 2.498 | 13.074 | 13.012 | |||||||
| Average Total | 30,20% | 30,75% | 25,69% | 27,33% | |||||||
| Minimum | 21 | 174 | 18,41% | 148 | 15,66% | 1 | 0 | 0,00% | 0 | 0,00% | |
| Maximum | 301 | 336 | 35,56% | 337 | 35,66% | 625 | 338 | 35,77% | 338 | 35,77% | |
| Systolic versus diatolic blood pressureb | Number of interactions | Number of interactions | |||||||||
| p-value | 0,78 | 0,72 | |||||||||
| Supine model with and without covariatesc | |||||||||||
| Systolic | Diastolic | ||||||||||
| F-test | p-value | 0,0024 | 0,0055 | ||||||||
| Number of total interactions detected | Full model | Model without co-variates | |||||||||
| Interactions | Fraction | Interactions | Fraction | ||||||||
| Systolic | 676 | 68,28% | 695 | 70,20% | |||||||
| Diastolic | 681 | 68,79% | 695 | 70,20% | |||||||
a The fraction is calculated as the number of significant interactions detected realtive to the maximal number of interaction possible
b Test of difference in number of interactions between diastolic and systolic blood pressures
c Test of the number of significant interactions in the two models. The number of interactions in the model with covariates (the fulle model)
is significant higher than in the resticted model without covariates.
Figure 3Partition of the population into 14 subpopulations using the supine blood pressure measurements as indicators and including the covariates in LPA-SEM procedure. The figure shows the distribution of the 14 subpopulations and the overall statistics of the study population. Similar distributions were obtained in the other models. A view of the subpopulations in the Supine model can be seen in Additional file 5.
Summary of epistasis and the hypertensive state in the Supine model
| Subpopulation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Entire population | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of subjects | 39 | 111 | 259 | 33 | 189 | 300 | 132 | 89 | 237 | 141 | 163 | 40 | 166 | 21 | |||
| Genetics | |||||||||||||||||
| Diastolic blood pressures | |||||||||||||||||
| Number of interactions | 307 | 316 | 294 | 334 | 257 | 310 | 307 | 238 | 276 | 337 | 302 | 336 | 306 | 148 | 676 | ||
| Percentage of possible (990) | 31,0% | 31,9% | 29,7% | 33,7% | 26,0% | 31,3% | 31,0% | 24,0% | 27,9% | 34,0% | 30,5% | 33,9% | 30,9% | 14,9% | 71,5% | ||
| Number of interactions curated3 | 101 | 136 | 126 | 120 | 111 | 142 | 130 | 114 | 119 | 140 | 143 | 119 | 121 | 94 | |||
| Percentage of possible (253) | 39,9% | 53,8% | 49,8% | 47,4% | 43,9% | 56,1% | 51,4% | 45,1% | 47,0% | 55,3% | 56,5% | 47,0% | 47,8% | 37,2% | |||
| Genetic valuesb: | |||||||||||||||||
| Average | 0,0338 | 0,0069 | 0,0032 | 0,0430 | 0,0049 | 0,0021 | 0,0059 | 0,0102 | 0,0031 | 0,0057 | 0,0039 | 0,0244 | 0,0049 | 0,1532 | |||
| Median | 0,0260 | 0,0060 | 0,0020 | 0,0233 | 0,0032 | 0,0014 | 0,0040 | 0,0077 | 0,0022 | 0,0041 | 0,0032 | 0,0180 | 0,0037 | 0,1081 | |||
| Maximum | 0,0322 | 0,0191 | 0,0285 | 0,0107 | 0,0371 | 0,0472 | 0,0182 | 0,0283 | 0,0214 | 0,0259 | |||||||
| Minimum | 0,0022 | 0,0003 | 0,0000 | 0,0029 | 0,0000 | 0,0001 | 0,0002 | 0,0002 | 0,0001 | 0,0002 | 0,0001 | 0,0015 | 0,0001 | 0,0099 | |||
| Systolic blood pressures | |||||||||||||||||
| Number of interactions | 307 | 318 | 298 | 230 | 257 | 321 | 306 | 238 | 275 | 334 | 295 | 336 | 307 | 174 | 681 | ||
| Percentage of possible (990) | 31,0% | 32,1% | 30,1% | 23,2% | 26,0% | 32,4% | 30,9% | 24,0% | 27,8% | 33,7% | 29,8% | 33,9% | 31,0% | 17,6% | 68,8% | ||
| Number of interactions curateda | 102 | 136 | 128 | 104 | 111 | 144 | 130 | 114 | 120 | 141 | 143 | 119 | 122 | 103 | |||
| Percentage of possible (253) | 40,3% | 53,8% | 50,6% | 41,1% | 43,9% | 56,9% | 51,4% | 45,1% | 47,4% | 55,7% | 56,5% | 47,0% | 48,2% | 40,7% | |||
| Genetic values: | |||||||||||||||||
| Average | 0,0334 | 0,0069 | 0,0032 | 0,0468 | 0,0049 | 0,0021 | 0,0060 | 0,0103 | 0,0031 | 0,0058 | 0,0040 | 0,0244 | 0,0048 | 0,1663 | |||
| Median | 0,0257 | 0,0059 | 0,0020 | 0,0335 | 0,0032 | 0,0014 | 0,0040 | 0,0077 | 0,0023 | 0,0042 | 0,0033 | 0,0180 | 0,0035 | 0,1116 | |||
| Maximum | 0,0321 | 0,0192 | 0,0285 | 0,0108 | 0,0372 | 0,0472 | 0,0183 | 0,0283 | 0,0214 | 0,0260 | |||||||
| Minimum | 0,0021 | 0,0002 | 0,0000 | 0,0052 | 0,0001 | 0,0001 | 0,0002 | 0,0004 | 0,0001 | 0,0001 | 0,0001 | 0,0015 | 0,0002 | 0,0089 | |||
| Blood pressures | |||||||||||||||||
| Diastolic blood pressures | |||||||||||||||||
| Mean | 69,9 | 68,3 | 82,9 | 75,2 | 89,5 | 79,7 | 88,3 | 79,1 | 95,6 | 78,6 | 80,1 | ||||||
| Std. Deviation | 4,1 | 3,5 | 2,1 | 2,2 | 6,9 | 1,5 | 3,3 | 2,8 | 5,0 | 6,1 | 10,1 | ||||||
| Std. Error | 0,4 | 0,2 | 0,2 | 0,1 | 0,6 | 0,2 | 0,2 | 0,2 | 0,4 | 0,5 | 0,2 | ||||||
| Lower Bound (95% CI) | 69,1 | 67,9 | 82,6 | 75,0 | 88,3 | 79,4 | 87,9 | 78,6 | 94,8 | 77,7 | 79,7 | ||||||
| Upper Bound (95% CI) | 70,7 | 68,8 | 83,2 | 75,5 | 90,7 | 80,0 | 88,7 | 79,5 | 96,4 | 79,5 | 80,6 | ||||||
| Minimum | 60,5 | 58,5 | 78,0 | 69,5 | 73,5 | 76,5 | 79,0 | 70,5 | 81,0 | 62,0 | 49,5 | ||||||
| Maximum | 79,5 | 79,0 | 89,5 | 81,0 | 107,5 | 84,0 | 97,5 | 84,5 | 108,5 | 92,5 | 132,5 | ||||||
| Systolic blood pressures | |||||||||||||||||
| Mean | 118,1 | 109,2 | 123,8 | 118,3 | 159,0 | 119,3 | 133,9 | 132,8 | 152,3 | 138,5 | 128,8 | ||||||
| Std. Deviation | 6,1 | 5,3 | 4,7 | 5,5 | 13,3 | 5,0 | 6,1 | 6,9 | 10,4 | 8,9 | 17,8 | ||||||
| Std. Error | 0,6 | 0,3 | 0,3 | 0,3 | 1,2 | 0,5 | 0,4 | 0,6 | 0,8 | 0,7 | 0,4 | ||||||
| Lower Bound (95% CI) | 117,0 | 108,5 | 123,2 | 117,7 | 156,7 | 118,3 | 133,2 | 131,7 | 150,7 | 137,1 | 177,0 | 128,0 | |||||
| Upper Bound (95% CI) | 119,3 | 109,8 | 124,5 | 118,9 | 161,3 | 120,4 | 134,7 | 134,0 | 153,9 | 139,8 | 129,6 | ||||||
| Minimum | 99,0 | 93,5 | 108,0 | 98,0 | 122,0 | 106,5 | 111,0 | 117,5 | 105.5 | 116,0 | 84,5 | ||||||
| Maximum | 130,5 | 124,0 | 135,5 | 132,5 | 189,0 | 131,5 | 147,0 | 150,5 | 179,5 | 162,0 | 211,0 | ||||||
| Hypertensive subjects (%) | |||||||||||||||||
| Diastolic | 0 | 0 | 0 | 0 | 47,7 | 0 | 16 | 16,3 | 88,3 | 42,2 | |||||||
| Systolic | 0 | 0 | 0 | 0 | 91,7 | 0 | 25,7 | 0 | 87,1 | 1,2 | |||||||
| Distribution of age groups | |||||||||||||||||
| 1 | 1,8 | 62,5 | 43,9 | 49,8 | 0,0 | 61,8 | 35,9 | 1,4 | 11,0 | 0,0 | |||||||
| 2 | 9,9 | 30,1 | 45,0 | 37,2 | 5,3 | 34,8 | 43,0 | 22,7 | 39,3 | 0,5 | |||||||
| 3 | 61,3 | 7,4 | 11,1 | 12,3 | 31,8 | 3,4 | 20,7 | 61,7 | 38,7 | 24,7 | |||||||
| 4 | 27,0 | 0,0 | 0,0 | 0,3 | 62,9 | 0,0 | 0,4 | 14,2 | 11,0 | 74,7 | |||||||
| Distribution of hypertensive subjects in age groups | |||||||||||||||||
| 1 | Diastolic | 0 | 0 | 0 | 0 | 0 | 0 | 34,1 | 0 | 88,9 | 0 | ||||||
| Systolic | 0 | 0 | 0 | 0 | 0 | 0 | 18,8 | 50 | 83,2 | 0 | |||||||
| 2 | Diastolic | 0 | 0 | 0 | 0 | 57,1 | 0 | 32,4 | 0 | 96,9 | 0 | ||||||
| Systolic | 0 | 0 | 0 | 0 | 100 | 0 | 15,7 | 31,2 | 90,6 | 0 | |||||||
| 3 | Diastolic | 0 | 0 | 0 | 0 | 52,4 | 0 | 28,6 | 0 | 84,1 | 0 | ||||||
| Systolic | 0 | 0 | 0 | 0 | 85,7 | 0 | 26,5 | 13,8 | 93,7 | 58,5 | |||||||
| 4 | Diastolic | 0 | 0 | 0 | 0 | 48,2 | 0 | 0 | 0 | 66,7 | 1,6 | ||||||
| Systolic | 0 | 0 | 0 | 0 | 96,4 | 0 | 0 | 0 | 88,9 | 41,3 | |||||||
a Restricted to one interaction per gene-pair
b Relative gene tic variance of phenotypic variance
The subpopulations in bold have relative genetic variance above 0.05.
Figure 4The core biochemical network of the ceramide/sphingosine-1-phosphate rheostat. A comprehensive core network is depicted including the possible source of free fatty acids synthesized de novo in the vascular bed (the fatty acid elongation enzyme, ELOV3), as well as the oxidative-redox system (GCLC and GCLM) which regulates neutral sphingomyelinase activity, a source of ceramides. These latter are only introduced as "summary" variables as the focus has been on the de novo pathway of ceramide synthesis. Node degrees are shown in the brackets.
Figure 5The networks constructed for all the subpopulations in the Supine model are merged including the interactions with maximal genetic values producing the network shown. This network compiles all detected interactions including the core metabolic network as shown in Figure 4 as well as indirect interactions.
Figure 6Subtracting the core network in Figure 4 from the complexed network in Figure 5 generate a network of epistasis excluding the metabolic flux.